Jounce Therapeutics, a clinical-stage immunotherapy company, terminated the $425m merger with Redx Pharma, a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis. Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, which led to Jounce entering into a merger agreement whereby Concentra will acquire Jounce through a cash tender offer